David M. Gershenson

34.1k total citations · 3 hit papers
406 papers, 21.6k citations indexed

About

David M. Gershenson is a scholar working on Reproductive Medicine, Surgery and Obstetrics and Gynecology. According to data from OpenAlex, David M. Gershenson has authored 406 papers receiving a total of 21.6k indexed citations (citations by other indexed papers that have themselves been cited), including 286 papers in Reproductive Medicine, 127 papers in Surgery and 117 papers in Obstetrics and Gynecology. Recurrent topics in David M. Gershenson's work include Ovarian cancer diagnosis and treatment (281 papers), Endometrial and Cervical Cancer Treatments (100 papers) and Intraperitoneal and Appendiceal Malignancies (59 papers). David M. Gershenson is often cited by papers focused on Ovarian cancer diagnosis and treatment (281 papers), Endometrial and Cervical Cancer Treatments (100 papers) and Intraperitoneal and Appendiceal Malignancies (59 papers). David M. Gershenson collaborates with scholars based in United States, Canada and United Kingdom. David M. Gershenson's co-authors include Karen H. Lu, Mitchell Morris, Elvio G. Silva, Thomas W. Burke, Michael T. Deavers, Charlotte C. Sun, Anaís Malpica, Charles Levenback, Patricia J. Eifel and David G. Mutch and has published in prestigious journals such as New England Journal of Medicine, Nature Communications and Journal of Clinical Oncology.

In The Last Decade

David M. Gershenson

398 papers receiving 21.1k citations

Hit Papers

align trajectories sort by overperformance

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Pelvic Radiation with Concurrent Chemotherapy Compared with Pelvic and Para-Aortic Radiation for High-Risk Cervical Cancer

1999 1.7k citations Mitchell Morris, Patricia J. Eifel et al. profile →
Pelvic Irradiation With Concurrent Chemotherapy Versus Pelvic and Para-Aortic Irradiation for High-Risk Cervical Cancer: An Update of Radiation Therapy Oncology Group Trial (RTOG) 90-01

2004 771 citations Patricia J. Eifel, Mitchell Morris et al. Journal of Clinical Oncology profile →
Prophylactic Surgery to Reduce the Risk of Gynecologic Cancers in the Lynch Syndrome

2006 516 citations Kathleen M. Schmeler, Henry T. Lynch et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
David M. Gershenson United States	76	12.0k	8.2k	5.9k	5.2k	4.2k	406	21.6k
David G. Mutch United States	68	6.9k 0.6×	9.4k 1.1×	4.6k 0.8×	4.3k 0.8×	4.0k 0.9×	449	19.1k
Nicoletta Colombo Italy	66	10.7k 0.9×	6.0k 0.7×	4.3k 0.7×	7.3k 1.4×	3.3k 0.8×	451	18.3k
Robert A. Soslow United States	85	10.4k 0.9×	11.2k 1.4×	3.3k 0.6×	4.3k 0.8×	4.8k 1.2×	426	23.6k
Frédéric Amant Belgium	66	9.0k 0.7×	8.7k 1.1×	3.5k 0.6×	7.2k 1.4×	3.7k 0.9×	554	21.9k
Richard R. Barakat United States	70	10.0k 0.8×	9.6k 1.2×	5.3k 0.9×	3.5k 0.7×	1.5k 0.4×	286	18.0k
Robert A. Burger United States	48	9.1k 0.8×	3.7k 0.5×	4.4k 0.7×	4.6k 0.9×	3.6k 0.9×	202	14.8k
Gunnar B. Kristensen Norway	59	7.6k 0.6×	4.4k 0.5×	3.8k 0.6×	4.3k 0.8×	3.6k 0.8×	266	14.7k
Karen H. Lu United States	72	8.3k 0.7×	5.3k 0.6×	2.1k 0.3×	6.8k 1.3×	7.4k 1.8×	427	21.6k
Thomas J. Herzog United States	64	6.2k 0.5×	6.1k 0.7×	3.3k 0.6×	3.2k 0.6×	1.8k 0.4×	334	13.3k
Carol Aghajanian United States	62	7.5k 0.6×	4.3k 0.5×	3.2k 0.5×	6.1k 1.2×	3.6k 0.9×	425	15.3k

Countries citing papers authored by David M. Gershenson

Since Specialization

Citations

This map shows the geographic impact of David M. Gershenson's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by David M. Gershenson with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites David M. Gershenson more than expected).

Fields of papers citing papers by David M. Gershenson

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by David M. Gershenson. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by David M. Gershenson. The network helps show where David M. Gershenson may publish in the future.

Co-authorship network of co-authors of David M. Gershenson

This figure shows the co-authorship network connecting the top 25 collaborators of David M. Gershenson. A scholar is included among the top collaborators of David M. Gershenson based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with David M. Gershenson. David M. Gershenson is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Celestino, Joseph, Reid T. Powell, Clifford Stephan, et al.. (2024). Gain-of-Function Chromatin Remodeling Activity of Oncogenic FOXL2C134W Reprograms Glucocorticoid Receptor Occupancy to Drive Granulosa Cell Tumors. Cancer Research. 85(5). 875–893. 1 indexed citations

How, Jeffrey, Bryan Fellman, Michael Frumovitz, et al.. (2024). Serial cytoreductive surgery and survival outcomes in recurrent adult-type ovarian granulosa cell tumors. American Journal of Obstetrics and Gynecology. 230(5). 544.e1–544.e13. 5 indexed citations

Hollis, Robert L., Richard Elliott, John C. Dawson, et al.. (2024). High throughput screening identifies dasatinib as synergistic with trametinib in low grade serous ovarian carcinoma. Gynecologic Oncology. 186. 42–52. 5 indexed citations

Matsuo, Koji, Hiroko Machida, Shinya Matsuzaki, et al.. (2020). Evolving population-based statistics for rare epithelial ovarian cancers. Gynecologic Oncology. 157(1). 3–11. 17 indexed citations

Peavey, Mary, Sara E. Arian, William E. Gibbons, et al.. (2016). On-Site Fertility Preservation Services for Adolescents and Young Adults in a Comprehensive Cancer Center. Journal of Adolescent and Young Adult Oncology. 6(2). 229–234. 8 indexed citations

Slomovitz, Brian M., Yunyun Jiang, Melinda S. Yates, et al.. (2015). Phase II Study of Everolimus and Letrozole in Patients With Recurrent Endometrial Carcinoma. Journal of Clinical Oncology. 33(8). 930–936. 201 indexed citations

Lu, Karen H., David S. Loose, Melinda S. Yates, et al.. (2013). Prospective Multicenter Randomized Intermediate Biomarker Study of Oral Contraceptive versus Depo-Provera for Prevention of Endometrial Cancer in Women with Lynch Syndrome. Cancer Prevention Research. 6(8). 774–781. 69 indexed citations

Gershenson, David M.. (2012). Treatment of Ovarian Cancer in Young Women. Clinical Obstetrics & Gynecology. 55(1). 65–74. 44 indexed citations

Yates, Melinda S., Larissa A. Meyer, Michael T. Deavers, et al.. (2011). Microscopic and Early-Stage Ovarian Cancers in BRCA1/2 Mutation Carriers: Building a Model for Early BRCA-Associated Tumorigenesis. Cancer Prevention Research. 4(3). 463–470. 43 indexed citations

10.

Kim, Tae Jin, Murali K. Ravoori, Charles N. Landen, et al.. (2007). Antitumor and Antivascular Effects of AVE8062 in Ovarian Carcinoma. Cancer Research. 67(19). 9337–9345. 78 indexed citations

11.

Gershenson, David M., Anna M. Miller, Victoria L. Champion, et al.. (2007). Reproductive and Sexual Function After Platinum-Based Chemotherapy in Long-Term Ovarian Germ Cell Tumor Survivors: A Gynecologic Oncology Group Study. Journal of Clinical Oncology. 25(19). 2792–2797. 127 indexed citations

12.

Kamat, Aparna A., Tae Jin Kim, Charles N. Landen, et al.. (2007). Metronomic Chemotherapy Enhances the Efficacy of Antivascular Therapy in Ovarian Cancer. Cancer Research. 67(1). 281–288. 113 indexed citations

13.

Bonome, Tomás, Dong-Choon Park, Mike Radonovich, et al.. (2005). Expression Profiling of Serous Low Malignant Potential, Low-Grade, and High-Grade Tumors of the Ovary. Cancer Research. 65(22). 10602–10612. 238 indexed citations

14.

Schmeler, Kathleen M., Pamela T. Soliman, Charlotte C. Sun, et al.. (2005). Endometrial cancer in young, normal-weight women. Gynecologic Oncology. 99(2). 388–392. 55 indexed citations

15.

Ward, Nancy E., Richard J. Epstein, Andrzej P. Kudelka, et al.. (2002). Treatment with HER-2 phosphorylation agonists enhance tumor ability to stimulate epitope specific CTL in vitro. Oncology Reports. 9(5). 929–35. 3 indexed citations

16.

Ramírez, Pedro T., Charles Levenback, Thomas W. Burke, et al.. (2001). Sigmoid Perforation Following Radiation Therapy in Patients with Cervical Cancer. Gynecologic Oncology. 82(1). 150–155. 19 indexed citations

17.

Lee, Tom V., Dong‐Kyu Kim, George E. Peoples, et al.. (2000). Secretion of CXC Chemokine IP-10 by Peripheral Blood Mononuclear Cells from Healthy Donors and Breast Cancer Patients Stimulated with HER-2 Peptides. Journal of Interferon & Cytokine Research. 20(4). 391–401. 10 indexed citations

18.

Morris, Mitchell, et al.. (1996). Transverse Colon Urinary Diversion in Gynecologic Oncology. Gynecologic Oncology. 63(1). 66–70. 17 indexed citations

19.

Zhang, X., et al.. (1989). Amplification and rearrangement of c-erb B proto-oncogenes in cancer of human female genital tract.. PubMed. 4(8). 985–9. 92 indexed citations

20.

Seski, Jan C., et al.. (1985). Surgical management of irradiation-induced small bowel damage.. PubMed. 65(4). 563–7. 20 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact